Joji Suzuki1, Michele L Matthews2, David Brick3, Minh-Thuy Nguyen3, Ajay D Wasan4, Robert N Jamison5, Andrew L Ellner6, Lori W Tishler7, Roger D Weiss8. 1. Instructor in Psychiatry, Harvard Medical School, Boston, Massachusetts; Division of Addiction Psychiatry, Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts. 2. Associate Professor of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences University, Boston, Massachusetts; Department of Anesthesia, Perioperative, and Pain Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 3. Harvard Medical School Center for Primary Care, Boston, Massachusetts. 4. Departments of Anesthesiology and Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Anesthesiology, Bringham and Women's Hospital, Boston, Massachusetts. 5. Professor of Anesthesia, Harvard Medical School, Boston, Massachusetts; Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts; Department of Anesthesia, Perioperative, and Pain Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 6. Instructor in Medicine, Harvard Medical School, Boston, Massachusetts; Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, Massachusetts; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts. 7. Assistant Professor of Medicine, Harvard Medical School, Boston, Massachusetts; Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, Massachusetts. 8. Professor of Psychiatry, Harvard Medical School, Boston, Massachusetts; Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, Massachusetts.
Abstract
OBJECTIVE: To implement a collaborative care management program with buprenorphine in a primary care clinic. DESIGN: Prospective observational study. SETTING: A busy urban academic primary care clinic affiliated with a tertiary care hospital. PARTICIPANTS: Opioid-dependent patients or patients with chronic pain using opioids nonmedically were recruited for the study. A total of 45 participants enrolled. INTERVENTIONS: Patients were treated with buprenorphine and managed by a supervising psychiatrist, pharmacist care manager, and health coaches. The care manager conducted buprenorphine inductions and all follow-up visits. Health coaches offered telephonic support. The psychiatrist supervised both the care manager and health coaches. MAIN OUTCOME MEASURES: Primary outcomes were treatment retention at 6 months, and change in the proportion of aberrant toxicology results and opioid craving scores from baseline to 6 months. After data collection, clinical outcomes were compared between opioid-dependent patients and patients with chronic pain using opioids nonmedically. Overall, 55.0 percent of participants (25/45) remained in treatment at 6 months. Primary care physicians (PCPs)' attitudes about opioid dependence treatment were surveyed at baseline and at 18 months. RESULTS: Forty-three patients (95.6 percent) accepted treatment and 25 (55.0 percent) remained in treatment at 6 months. The proportion of aberrant urine toxicology results decreased significantly from baseline to 6 months (p < 0.01). Craving scores significantly decreased from baseline to 6 months (p < 0.01). Opioid-dependent patients, as opposed to patients with chronic pain using opioids nonmedically, were significantly more likely to complete 6 months of treatment (p < 0.05). PCPs' confidence in treating opioid dependence in primary care increased significantly from baseline to 18 months postimplementation (p < 0.01). CONCLUSION: Collaborative care management for opioid dependence with buprenorphine may be feasible in a primary care clinic. More research is needed to understand the role of buprenorphine in managing patients with chronic pain using opioids nonmedically.
OBJECTIVE: To implement a collaborative care management program with buprenorphine in a primary care clinic. DESIGN: Prospective observational study. SETTING: A busy urban academic primary care clinic affiliated with a tertiary care hospital. PARTICIPANTS: Opioid-dependent patients or patients with chronic pain using opioids nonmedically were recruited for the study. A total of 45 participants enrolled. INTERVENTIONS:Patients were treated with buprenorphine and managed by a supervising psychiatrist, pharmacist care manager, and health coaches. The care manager conducted buprenorphine inductions and all follow-up visits. Health coaches offered telephonic support. The psychiatrist supervised both the care manager and health coaches. MAIN OUTCOME MEASURES: Primary outcomes were treatment retention at 6 months, and change in the proportion of aberrant toxicology results and opioid craving scores from baseline to 6 months. After data collection, clinical outcomes were compared between opioid-dependent patients and patients with chronic pain using opioids nonmedically. Overall, 55.0 percent of participants (25/45) remained in treatment at 6 months. Primary care physicians (PCPs)' attitudes about opioid dependence treatment were surveyed at baseline and at 18 months. RESULTS: Forty-three patients (95.6 percent) accepted treatment and 25 (55.0 percent) remained in treatment at 6 months. The proportion of aberrant urine toxicology results decreased significantly from baseline to 6 months (p < 0.01). Craving scores significantly decreased from baseline to 6 months (p < 0.01). Opioid-dependent patients, as opposed to patients with chronic pain using opioids nonmedically, were significantly more likely to complete 6 months of treatment (p < 0.05). PCPs' confidence in treating opioid dependence in primary care increased significantly from baseline to 18 months postimplementation (p < 0.01). CONCLUSION: Collaborative care management for opioid dependence with buprenorphine may be feasible in a primary care clinic. More research is needed to understand the role of buprenorphine in managing patients with chronic pain using opioids nonmedically.
Authors: Jürgen Unützer; Wayne Katon; Christopher M Callahan; John W Williams; Enid Hunkeler; Linda Harpole; Marc Hoffing; Richard D Della Penna; Polly Hitchcock Noël; Elizabeth H B Lin; Patricia A Areán; Mark T Hegel; Lingqi Tang; Thomas R Belin; Sabine Oishi; Christopher Langston Journal: JAMA Date: 2002-12-11 Impact factor: 56.272
Authors: Roger D Weiss; Margaret L Griffin; Carissa Mazurick; Benjamin Berkman; David R Gastfriend; Arlene Frank; Jacques P Barber; Jack Blaine; Ihsan Salloum; Karla Moras Journal: Am J Psychiatry Date: 2003-07 Impact factor: 18.112
Authors: Gail D'Onofrio; Marek C Chawarski; Patrick G O'Connor; Michael V Pantalon; Susan H Busch; Patricia H Owens; Kathryn Hawk; Steven L Bernstein; David A Fiellin Journal: J Gen Intern Med Date: 2017-02-13 Impact factor: 5.128
Authors: Amy Werremeyer; Jolene Bostwick; Carla Cobb; Tera D Moore; Susie H Park; Cristofer Price; Jerry McKee Journal: Ment Health Clin Date: 2020-11-05
Authors: Nodira Codell; A Taylor Kelley; Audrey L Jones; Matthew T Dungan; Natalie Valentino; Ana I Holtey; Tania J Knight; Amy Butz; Christina Gallop; Sean Erickson; Jeremy Patton; Laura Jane Hyte-Richins; Benjamin Z Rollins; Adam J Gordon Journal: Am J Drug Alcohol Abuse Date: 2020-12-10 Impact factor: 3.829
Authors: Hope E M Schwartz; Camden P Bay; Brittany M McFeeley; Taylor J Krivanek; Kirk R Daffner; Seth A Gale Journal: Alzheimers Dement (N Y) Date: 2019-11-12
Authors: Steffani R Bailey; Jennifer A Lucas; Heather Angier; Rebecca E Cantone; Joan Fleishman; Brian Garvey; Deborah J Cohen; Rebecca E Rdesinski; Leah Gordon Journal: J Subst Abuse Treat Date: 2021-06-24
Authors: Marcus A Bachhuber; Cole Thompson; Ann Prybylowski; José Benitez; Silvana Mazzella; David Barclay Journal: Subst Abus Date: 2018-05-04 Impact factor: 3.984